Physician profile
William Cheung
NPI 1043664139
$3,281.26
in general payments reported to CMS, 2019-2025
30 companies · $575 in 2025
The $575 reported for 2025 was more than what 93% of Emergency Medicine providers received nationally (typical 2025 total: $57.10).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $97.26 · 2020: $57.71 · 2021: $801 · 2022: $259 · 2023: $867 · 2024: $624 · 2025: $575.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,066.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,066.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $535.09 | 2022-2025 | Reblozyl, Pomalyst |
| E.R. Squibb & Sons, L.L.C. | $507.17 | 2019-2024 | Opdivo, Opdualag |
| Genentech USA, INC. | $291.12 | 2021-2022 | |
| Glaxosmithkline, LLC. | $265.83 | 2023-2025 | Trelegy Ellipta, Ojjaara, Shingrix |
| Exelixis INC. | $149.44 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $139.74 | 2024-2025 | |
| Mallinckrodt Hospital Products INC. | $136.30 | 2021 | |
| Azurity Pharmaceuticals, INC. | $128.84 | 2025 | Danziten |
| Abbvie INC. | $121.52 | 2021 | |
| Lilly USA, LLC | $120.54 | 2020-2024 | Mounjaro |
| Sumitomo Pharma America, INC. | $110.40 | 2023-2025 | Orgovyx |
| Phathom Pharmaceuticals, INC. | $103.10 | 2024 | Voquezna |
| Astrazeneca Pharmaceuticals LP | $72.70 | 2023-2024 | Airsupra, Enhertu, Andexxa |
| Janssen Biotech, INC. | $66.14 | 2023-2025 | Erleada, Balversa, Akeega |
| Stemline Therapeutics INC. | $62.75 | 2023-2024 | Orserdu |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $55.30 | 2021 | |
| Novartis Pharmaceuticals Corporation | $50.75 | 2023 | |
| Aveo Pharmaceuticals, INC. | $49.82 | 2023-2024 | Fotivda |
| Seagen INC. | $42.36 | 2020-2023 | Adcetris |
| Puma Biotechnology, INC. | $40.97 | 2021 | |
| Daiichi Sankyo INC. | $38.62 | 2022-2024 | Enhertu |
| Genzyme Corporation | $26.99 | 2024 | |
| Exact Sciences Corporation | $26.06 | 2025 | Cologuard Collection Kit |
| Aimmune Therapeutics, INC. | $24.69 | 2025 | Zenpep |
| Mirati Therapeutics, INC. | $23.11 | 2024 | Krazati |
| Shield Therapeutics INC | $20.63 | 2024 | |
| Mannkind Corporation | $19.23 | 2021 | |
| Zoll Circulation INC | $18.30 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.04 | 2024 | Fruzaqla |
| Esperion Therapeutics, INC. | $16.71 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Cheung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.